Page last updated: 2024-08-24

triazoles and oxidopamine

triazoles has been researched along with oxidopamine in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.00)18.7374
1990's5 (20.00)18.2507
2000's10 (40.00)29.6817
2010's8 (32.00)24.3611
2020's1 (4.00)2.80

Authors

AuthorsStudies
Hamilton, TC; Longman, SD1
di Chiara, G; Morelli, M; Pinna, A; Wardas, J1
Fenu, S; Morelli, M; Ongini, E; Pinna, A1
Cristalli, G; Morelli, M; Pinna, A; Wardas, J1
Fenu, S; Morelli, M1
Bloch, B; Fourreau, L; Fredholm, BB; Gonon, F; Le Moine, C; Svenningsson, P1
Fenu, S; Morelli, M; Pinna, A1
Morelli, M; Pinna, A1
Corsi, C; Gianfriddo, M; Melani, A; Morelli, M; Pedata, F; Pinna, A1
Carta, AR; Morelli, M; Pinna, A; Tronci, E1
Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L1
Chang, H; Conlon, PR; Engber, TM; Haque, S; Kiesman, WF; Kumaravel, G; Petter, RC; Sha, L; Wang, J; Whalley, ET; Yao, G1
Dexter, DT; Dhankot, A; Gillies, GE; McArthur, S; Murray, HE1
Jenner, P; Ramsay Croft, N; Rose, S1
Asai, M; Matsuya, T; Miyoshi, S; Mizoguchi, H; Murakami, Y; Nagai, T; Nishimura, S; Noda, A; Sato, K; Takuma, K; Yamada, K1
Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E1
Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R1
Dziubina, A; Gołembiowska, K1
Bhattacharjee, AK; Chen, X; Jacobson, KA; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Shinkre, B; Trenkle, WC1
Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N1
Downey, P; Michel, A; Nicolas, JM; Scheller, D1
Borsini, F; Caprioli, A; Di Serio, S; Lombardo, K; Minetti, P; Pace, S; Riccioni, T; Stasi, MA; Vertechy, M1
A Figge, D; Standaert, DG1
Agostinho, P; Andrade, GM; Canas, PM; Carmo, M; Cunha, RA; Duarte, FV; Fernandes, FD; Gonçalves, FQ; Oses, JP; Palmeira, CM; Tomé, AR1
Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M1

Other Studies

25 other study(ies) available for triazoles and oxidopamine

ArticleYear
A comparison of the cardiovascular and sedative actions of the alpha-adrenoceptor agonists, FLA-136 and clonidine, in the rat.
    British journal of pharmacology, 1982, Volume: 75, Issue:1

    Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Clonidine; Drug Interactions; Heart Rate; Hemodynamics; Hydroxydopamines; Hypnotics and Sedatives; Injections, Intraventricular; Male; Methohexital; Naloxone; Oxidopamine; Rats; Rats, Inbred Strains; Triazoles; Yohimbine

1982
Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats.
    The European journal of neuroscience, 1996, Volume: 8, Issue:6

    Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Denervation; Male; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Rotation; Triazoles; Xanthines

1996
Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
    European journal of pharmacology, 1997, Feb-26, Volume: 321, Issue:2

    Topics: Animals; Behavior, Animal; Brain Diseases; Dopamine Agonists; Drug Synergism; Gene Expression; Genes, fos; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Dopamine D2; Substantia Nigra; Triazoles

1997
Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas.
    Brain research, 1997, Jun-06, Volume: 759, Issue:1

    Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Dopamine Agonists; Immunohistochemistry; Limbic System; Male; Oxidopamine; Phenethylamines; Proto-Oncogene Proteins c-fos; Purinergic Antagonists; Purinergic P1 Receptor Agonists; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Triazoles

1997
Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors.
    The European journal of neuroscience, 1998, Volume: 10, Issue:5

    Topics: Animals; Apomorphine; Caffeine; Central Nervous System Stimulants; Dopamine Agonists; Male; Motor Activity; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Stimulation, Chemical; Triazoles; Xanthines

1998
Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons.
    Neuroscience, 1999, Volume: 89, Issue:3

    Topics: Adenosine; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Design; Gene Expression Regulation; Genes, fos; Globus Pallidus; In Situ Hybridization; Male; Models, Neurological; Nerve Tissue Proteins; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinolines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; RNA, Messenger; Triazoles; Tyrosine 3-Monooxygenase

1999
Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Synapse (New York, N.Y.), 2001, Mar-01, Volume: 39, Issue:3

    Topics: Animals; Dopamine Agents; Drug Tolerance; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Stereotyped Behavior; Sympathectomy, Chemical; Triazoles

2001
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2001, Volume: 22, Issue:1

    Topics: Animals; Antiparkinson Agents; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Levodopa; Male; Motor Activity; Neostriatum; Neural Pathways; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Substantia Nigra; Sympatholytics; Triazoles

2001
Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats.
    European journal of pharmacology, 2003, Mar-07, Volume: 464, Issue:1

    Topics: Animals; Corpus Striatum; Denervation; Dopamine; Glutamic Acid; Male; Microdialysis; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Time Factors; Triazoles

2003
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; RNA, Messenger; Time; Triazoles

2003
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles

2003
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
    Bioorganic & medicinal chemistry letters, 2005, Feb-01, Volume: 15, Issue:3

    Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Alkynes; Animals; Catalepsy; Cerebral Cortex; Disease Models, Animal; Mice; Oxidopamine; Parkinson Disease; Pyrazines; Rats; Structure-Activity Relationship; Triazoles

2005
Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
    Journal of neurochemistry, 2007, Volume: 100, Issue:3

    Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Cell Survival; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Resistance; Estrogens; Female; Male; Nerve Degeneration; Neural Pathways; Neuronal Plasticity; Neurotoxins; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sex Characteristics; Substantia Nigra; Triazoles

2007
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Brain research, 2007, Feb-16, Volume: 1133, Issue:1

    Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles

2007
Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
    Journal of pharmacological sciences, 2007, Volume: 103, Issue:3

    Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred ICR; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Rotation; Triazoles

2007
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    European journal of pharmacology, 2007, Jul-02, Volume: 566, Issue:1-3

    Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles

2007
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Neuropharmacology, 2010, Volume: 58, Issue:3

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae

2010
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
    Neurotoxicity research, 2012, Volume: 21, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles

2012
Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425.
    Nuclear medicine and biology, 2011, Volume: 38, Issue:6

    Topics: Animals; Autoradiography; Biological Transport; Injections; Male; Neostriatum; Oxidopamine; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Quinpirole; Raclopride; Radiochemistry; Rats; Receptor, Adenosine A2A; Triazoles

2011
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2012, Volume: 340, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase

2012
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Combination; Levodopa; Mass Spectrometry; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Purines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles

2014
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    European journal of pharmacology, 2015, Aug-15, Volume: 761

    Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Basal Ganglia; Binding, Competitive; Catalepsy; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; HEK293 Cells; Humans; Injections, Intraperitoneal; Ligands; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Transfection; Triazoles

2015
Dysregulation of BET proteins in levodopa-induced dyskinesia.
    Neurobiology of disease, 2017, Volume: 102

    Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles

2017
Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A
    British journal of pharmacology, 2019, Volume: 176, Issue:18

    Topics: 5'-Nucleotidase; Adenosine; Adenosine A2 Receptor Antagonists; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cell Line, Tumor; Humans; Male; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats, Wistar; Receptor, Adenosine A2A; Triazoles

2019
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
    Neuropharmacology, 2021, 09-15, Volume: 196

    Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha

2021